GlaxoSmithKline Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (346)

Latest Posts

About This Stock More About This Stock
E Breaking Down VBI Vaccines' Pipeline: Descriptions And Catalysts
Article By: Samuel Rae
Saturday, February 18, 2017 1:12 PM EDT
Here's a look at VBI Vaccines' (VBIV) pipeline and the events that should drive value for the company going forward; with caveats.
In this article: GSK, SNY, VBIV Also: OPK
Read
Week In Review: China To Add 300 Drugs To National Reimbursement Drug List
Article By: ChinaBio® Today
Saturday, February 4, 2017 1:21 PM EDT
According to sources, China is getting close to announcing a revised National Reimbursement Drug List, the group of drugs covered by China's national insurance plan. 130 will be chemical drugs and the rest will be traditional Chinese medicines.
In this article: AZN, GSK, FGEN
Read
Trump + Stocks: The Week In Review
Article By: The Fly
Friday, January 13, 2017 7:44 PM EDT
Weekly recap of stocks that are being impacted, or are predicted to be impacted, by the comments, actions and policies of President-elect Trump and his administration.
In this article: GSK, JNJ, JPM, LLY, LMT Also: AXP, NVS, PFE, PNR, ROP, SNY, EHTH, TRS, ENDP, MYL, MNK
Read
E Last London Letter
Article By: Vivian Lewis
Saturday, January 7, 2017 5:03 PM EDT
We present some insight on various international stocks on the move.
In this article: ALKS, AZSEY, BABA, BNTC, FAX, FBASF, FCO, GSK, MXCHF, MXE, NOK, SLB, SLFPY, TEVA, VR
Read
Merck (MRK) Does Well In 2016: Reasons For Outperformance
Article By: Zacks Investment Research
Sunday, January 1, 2017 6:09 PM EDT
Like many of its peers, Merck is facing generic competition and pricing pressure for some products. Yet, we believe its diversified business model, deep pipeline and strong financial position will continue to help the company navigate tough times.
In this article: AMGN, GSK, MRK, PFE
Read

PARTNER HEADLINES

Latest Tweets for $GSK

No tweets yet!